Whereas it is likely that patients with Basal-like breast cancer could benefit from CA9- and CA13-targeted therapy (Fig. 5), our current findings show that patients with HER2-enriched breast cancer will likely follow a more severe disease trajectory if treated with a carbonic anhydrase inhibitor. This evidence concerns the gene CA9 and breast cancer.